Data completeness
2/8 — Basic
BRANCHAMIN 4% (amino acids) by Baxter. Approved for muscle atrophy, muscle loss, muscle anabolism and 10 more indications.
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRANCHAMIN 4% is a branched-chain amino acid (BCAA) injectable formulation indicated for muscle atrophy, muscle loss, and anabolism across multiple disease states including chronic kidney disease, traumatic brain injury, and cancer-related cachexia. The product works by providing essential amino acids to support protein synthesis and reduce catabolism in metabolically stressed patients. It is administered intravenously as a nutritional support therapy.
Pre-Launch
Pre-launch stage indicates an emerging product with potential for team expansion once regulatory approval is obtained and commercialization begins.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Worked on BRANCHAMIN 4% at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.